Published in Gene on June 27, 2000
Positively regulated bacterial expression systems. Microb Biotechnol (2008) 1.14
Generation and validation of a Shewanella oneidensis MR-1 clone set for protein expression and phage display. PLoS One (2008) 0.88
Identification and characterization of beta-lactamase inhibitor protein-II (BLIP-II) interactions with beta-lactamases using phage display. Protein Eng Des Sel (2010) 0.85
Identification of a β-lactamase inhibitory protein variant that is a potent inhibitor of Staphylococcus PC1 β-lactamase. J Mol Biol (2011) 0.81
Use of periplasmic target protein capture for phage display engineering of tight-binding protein-protein interactions. Protein Eng Des Sel (2011) 0.75
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
Amino acid sequence determinants of beta-lactamase structure and activity. J Mol Biol (1996) 2.24
Natural history of recurrent urinary tract infections in women. Rev Infect Dis (1991) 2.05
Characterization of TEM-1 beta-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. J Biol Chem (1994) 1.72
A natural polymorphism in beta-lactamase is a global suppressor. Proc Natl Acad Sci U S A (1997) 1.71
Treatment of the acute urethral syndrome. N Engl J Med (1981) 1.71
Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase. J Bacteriol (1996) 1.65
Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime. J Biol Chem (1996) 1.63
Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind, placebo-controlled trial. Ann Intern Med (1980) 1.61
A secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation. Proc Natl Acad Sci U S A (2001) 1.58
beta-Lactamases: protein evolution in real time. Trends Microbiol (1998) 1.44
Treatment of cystitis in women with a single dose of trimethoprim-sulfamethoxazole. Rev Infect Dis (1982) 1.33
Cephalosporin substrate specificity determinants of TEM-1 beta-lactamase. J Biol Chem (1997) 1.25
Identification of residues critical for metallo-beta-lactamase function by codon randomization and selection. Protein Sci (2001) 1.23
Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of beta-lactamases. J Biol Chem (1999) 1.20
Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics. J Infect Dis (2000) 1.17
Effect of threonine-to-methionine substitution at position 265 on structure and function of TEM-1 beta-lactamase. Antimicrob Agents Chemother (1994) 1.16
Systematic mutagenesis of the yeast mating pheromone receptor third intracellular loop. J Biol Chem (1994) 1.11
Management of recurrent urinary tract infections with patient-administered single-dose therapy. Ann Intern Med (1985) 1.10
The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics. J Biol Chem (1998) 1.08
Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med (1987) 1.02
The rate-limiting step in the folding of the cis-Pro167Thr mutant of TEM-1 beta-lactamase is the trans to cis isomerization of a non-proline peptide bond. Proteins (1996) 0.97
Design of potent beta-lactamase inhibitors by phage display of beta-lactamase inhibitory protein. J Biol Chem (2000) 0.93
Roles of amino acids 161 to 179 in the PSE-4 omega loop in substrate specificity and in resistance to ceftazidime. Antimicrob Agents Chemother (1998) 0.92
Amino acid sequence determinants of extended spectrum cephalosporin hydrolysis by the class C P99 beta-lactamase. J Biol Chem (2001) 0.92
Identification of residues in beta-lactamase critical for binding beta-lactamase inhibitory protein. J Biol Chem (1999) 0.89
Identification and characterization of beta-lactamase inhibitor protein-II (BLIP-II) interactions with beta-lactamases using phage display. Protein Eng Des Sel (2010) 0.85
Binding properties of a peptide derived from beta-lactamase inhibitory protein. Antimicrob Agents Chemother (2001) 0.85
Structure-function analysis of alpha-helix H4 using PSE-4 as a model enzyme representative of class A beta-lactamases. Protein Eng (2000) 0.84
Alanine-scanning mutagenesis reveals residues involved in binding of pap-3-encoded pili. J Bacteriol (1994) 0.84
Clinical and microbiological features of persistent or recurrent nongonococcal urethritis in men. J Infect Dis (1988) 0.82
Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases. Antimicrob Agents Chemother (1998) 0.81
Enzymes involved in oxygen detoxification during development of Drosophila melanogaster. Experientia (1983) 0.81
Urinary prophylaxis with trimethoprim and trimethoprim-sulfamethoxazole: efficacy, influence on the natural history of recurrent bacteriuria, and cost control. Rev Infect Dis (1982) 0.79
Protein minimization by random fragmentation and selection. Protein Eng (2001) 0.78
Susceptibility of beta-lactamase to core amino acid substitutions. Protein Eng (1999) 0.77
Is antimicrobial prophylaxis of urinary tract infections cost effective? Ann Intern Med (1981) 0.77
Display of functional beta-lactamase inhibitory protein on the surface of M13 bacteriophage. Antimicrob Agents Chemother (1998) 0.76